Park Glen D, Mitchel Jules T
Target Health Inc, New York, New York.
Ann N Y Acad Sci. 2016 Jun;1374(1):10-6. doi: 10.1111/nyas.13126. Epub 2016 Jun 23.
While the development of medical products and approval by the U.S. Food and Drug Administration (FDA) is well known, the development of countermeasures against exposure to toxic levels of radiation, chemicals, and infectious agents requires special consideration, and there has been, to date, little experience in working with the FDA to obtain approval of these products. The FDA has published a regulation entitled "Approval of Biological Products when Human Efficacy Studies are not Ethical or Feasible." This regulation, known simply as the "Animal Rule," was designed to permit approval or licensing of drugs and biologics when efficacy studies in humans are not ethical or feasible. To date, 12 products have been approved under the Animal Rule. It is highly recommended that sponsors of products that are to be developed under the Animal Rule meet with the FDA and other government entities early in the development process to ensure that the efficacy and safety studies that are planned will meet the FDA's requirements for approval of the product.
虽然医疗产品的研发及获得美国食品药品监督管理局(FDA)的批准广为人知,但针对辐射、化学物质和传染源的毒性暴露制定应对措施则需要特殊考量,而且迄今为止,在与FDA合作以获得这些产品的批准方面几乎没有经验。FDA已发布一项名为“人体有效性研究不道德或不可行时生物制品的批准”的法规。这项法规简称为“动物规则”,旨在允许在人体有效性研究不道德或不可行时批准或许可药物及生物制品。迄今为止,已有12种产品根据“动物规则”获得批准。强烈建议根据“动物规则”研发产品的申办者在研发过程早期与FDA及其他政府实体进行沟通,以确保计划开展的有效性和安全性研究能够满足FDA对产品批准的要求。